Symposia submission guidelines


Dear Colleagues,

On behalf of the Organizing and Program Committees, it is with great pleasure that we would like to announce our 4th Trisomy 21 Research Society (T21RS) International Conference, to be held from June 9-12, 2022 in Long Beach, California.  Building on the success of the recent 2021 Virtual Meeting, the T21RS meeting in 2022 will be a hybrid in person/virtual meeting to continue to provide and expand access to those members who cannot attend in person. We hope to see you there.

The T21RS meetings are devoted to advancing both basic and clinical science in Down syndrome and related areas. The goals of the meeting are to provide a venue for the presentation of exciting and innovative research on Down syndrome. By building on the success of the last T21RS meetings, we aim to engage new researchers in the field and to promote collaboration.

The Scientific Program Committee is requesting proposals for symposia in basic and translational research in Down syndrome. We welcome symposium proposals from multiple disciplines, including, but not limited to, Down syndrome related disorders (e.g. leukemia, autoimmune diseases, Alzheimer disease), mechanisms underlying developmental challenges (e.g. language, cognition, behavior), pharmaceutical research, new technologies, sociological aspects, or important theoretical papers that foster diversity and debate. We encourage both established and junior investigators to contribute to the program of the meeting. We welcome preclinical and clinical science, ranging from molecular biology to human research, and especially topics that bridge scientific disciplines.

We encourage you to help us make the 2022 T21RS meeting in Long Beach a success! Proposals will be accepted only from T21RS members.  If you are not a T21RS member, please join at

Instructions for symposium proposals

Please include:

  1. A descriptive symposium title
  2. A short outline describing the topic and its relevance to the field (max. 2000 characters with spaces, about 250 words).
  3. Three lecture titles and associated speaker information (with one back-up speaker).

This is an international meeting and we value a diverse pool of speakers, so please consider speakers from various countries. Gender balance is also important. Preference will be given to proposals that include at least one presentation from a junior investigator. Formal approval from the proposed speakers is not yet necessary. Symposia that make connections between clinical, behavioral, and basic science or include the combination of multidisciplinary approaches around a common theme, are warmly invited. Symposium organizers will have the opportunity to select an extra short talk from a young investigator, from a list of selected oral communications provided by the Program Committee.


Please submit proposals before February 14, 2022.



Theme 1. Genomic and epigenetic mechanisms: Genetics, genomics, epigenetics, other -omics (transcriptome, metabolome, proteome, exposome, single-cell etc.), 3D genome organisation, multiomic modelling

Theme 2. Molecular and Cellular Mechanisms: Neurobiological, immunological, metabolism, synaptic mechanisms, plasticity, neuronal networks, etc

Theme 3. Experimental models: Animal models, cellular models, organoids, stem cells and reprogramming, etc.

Theme 4. Cognition and Behavior: Clinical and preclinical studies on cognition and behaviour, intellectual disability, language, behavior, emotion, executive functions, sex-specific differences, neuropsychological evaluation tools

Theme 5. Neurodegeneration and Ageing: Alzheimer disease in Down syndrome, neuropathology, immunosenescence, cognitive decline, etc.

Theme 6. Neurodevelopment: Neuropathology, neurogenesis, cell proliferation and differentiation, synaptogenesis, nervous system patterning, etc.

Theme 7. Co-occurring Illnesses: Cancer/ leukemia, psychiatric disorders, metabolic disorders, sensory disorders, cardiovascular diseases, etc.

Theme 8. Therapeutic intervention: Pharmacological/non-pharmacological interventions, neurotherapy, preclinical drug development, experimental therapeutics, clinical trials

Theme 9. Diagnosis and Evaluation: Biomarkers, neuroimaging, outcome measures

Theme 10. Other

Thank you on behalf of the Scientific Program Committee,